WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014198852) A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/198852 International Application No.: PCT/EP2014/062284
Publication Date: 18.12.2014 International Filing Date: 12.06.2014
Chapter 2 Demand Filed: 05.05.2015
IPC:
A61K 35/76 (2015.01) ,A61P 35/00 (2006.01)
Applicants: PSIOXUS THERAUPEUTICS LIMITED[GB/GB]; 154B Milton Park Abingdon Oxfordshire OX14 4SD, GB
Inventors: BEADLE, John, William; GB
FISHER, Kerry; GB
WILKINSON BLANC, Christine; GB
Agent: HAMBLETON, Bernadette; Sterling IP Orion House Bessemer Road Welwyn Garden City Hertfordshire AL7 1HH, GB
Priority Data:
1310698.414.06.2013GB
1405140.322.03.2014GB
1406509.810.04.2014GB
Title (EN) A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
(FR) POSOLOGIE ET FORMULATIONS POUR ADÉNOVIRUS DE TYPE B
Abstract:
(EN) The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1x1010 to 1x1014 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2x1010 particles per minute to 2x1012 particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.
(FR) Cette divulgation concerne une méthode pour traiter un patient humain comprenant l'étape d'administration par voie systémique de multiples doses d'une formulation parentérale d'un adénovirus oncolytique de sous-groupe B capable de réplication au cours d'un seul cycle de traitement. La dose totale administrée à chaque dose est dans la plage de 1x1010 à 1x1014 particules virales, et chaque dose de virus est administrée en l'espace de 1 à 90 minutes, par exemple à une vitesse d'administration de particules virales dans la plage de 2x1010 à 2x1012 particules par minute. Cette divulgation concerne en outre des formulations desdits adénovirus oncolytiques et des polythérapies basées sur lesdits virus et sur des formulations avec d'autres agents thérapeutiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)